Drug profile · INN
pegaptanib
MACUGEN
pegaptanib (MACUGEN) is a vascular endothelial growth factor a antagonist.
EMA: withdrawn Sensory organs (S01) S01LA03
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — pegaptanib
- Class
- Sensory organs (S01)
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.83
Quick answer
pegaptanib (MACUGEN) is a vascular endothelial growth factor a antagonist.
Key facts
INN pegaptanib
Brand MACUGEN
Mechanism Vascular endothelial growth factor A antagonist
Target Vascular endothelial growth factor A, long form
Therapeutic class Sensory organs (S01)
ATC code S01LA03
Mechanism of action
Vascular endothelial growth factor A antagonist
Primary target: Vascular endothelial growth factor A, long form
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | withdrawn | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is pegaptanib?
pegaptanib (MACUGEN) is a vascular endothelial growth factor a antagonist.
What is the brand name for pegaptanib?
MACUGEN is a marketed brand name for pegaptanib. Check FDA Drugs@FDA for the current US label holder and prescribing information.